WuXi Biologics increases issued shares through option exercises

WuXi Biologics (Cayman) Inc. has disclosed changes in its issued shares, reporting a closing balance of 4,108,098,791 ordinary shares as of April 8, 2025. The increase is primarily attributed to the exercise of share options under the Pre-IPO Share Option Scheme adopted on January 5, 2016. Throughout the period from April 1 to April 7, 2025, a total of 313,674 shares were issued through this scheme at prices ranging from HKD 1.29 to HKD 3.86. Additionally, 61,531 shares were issued for share awards and options to non-director participants. The company also repurchased 14,000,000 shares for cancellation at HKD 17.76 on April 8.